Summary
The clinical pharmacokinetics of clozapine, an atypical neuroleptic, was evaluated in 10 chronic schizophrenic male patients after intravenous and oral administration. The mean equilibrium-state concentration ratio between blood and plasma was experimentally determined to be 0.87. The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively. Plasma concentration peaked on average at 3 h. The mean volume of distribution at steady-state and the terminal half-life was 1.6 l/kg and 10.3 h, respectively. A large fraction of the dose is most probably metabolized by some extrahepatic presystemic routes. The large inter-individual variability in the bioavailability and clearance is probably the main reason for large variation in the steady-state plasma level in patients receiving the same oral dosage regimen.
Similar content being viewed by others
References
Andén NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25: 346–348
Nybäck H, Sedvall G (1976) Effects of neuroleptics on striatal dopamine synthesized from14C-tyrosine. Pharmacol Ther 2: 49–63
Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A (1972) Effects of clozapine on cerebral catecholaminergic neuron systems. Br J Pharmacol 46: 736–740
Fog R (1975) Neuroleptic action of clozapine injected into various brain areas in rats. Int Pharmacopsychiatry 10: 89–93
Sayers AC, Bürki HR, Ruch W, Asper A (1975) Neurolepticinduced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 41: 97–104
Angst J, Jaenicke U, Padrutt A, Scharfetter C (1971) Results of a double blind trial of leponex in comparison with levomepromazine. Pharmakopsychiatry 4: 192–200
Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410–424
Ekblom B, Häggström JE (1974) Clozapine (LeponexR) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16: 945–957
Leon CA (1979) Therapeutic effects of clozapine. A 4-year follow-up of a controlled clinical trial. Acta Psychiatr Scand 59: 471–480
Anderman B, Griffith RW (1977) Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 11: 199–201
Thorup M, Fog R (1977) Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors. Acta Psychiatr Scand 55: 123–126
Hakman L, Gabrielsson J (1986) MAXFIT, A User's Guide. Dept. of Biopharmaceutics and Pharmacokinetics, Uppsala University, Sweden
Rowland M, Tozer TN (1980) Clinical Pharmacokinetics, concepts and applications. Lea and Febiger, Philadelphia
Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York Basel
Wait JV, Clarke III F (1974) DARE-P, a portable digital simulation system. University of Ariona
Statistical analysis system (SAS), User's guide (1979) SAS Institute Inc., North Carolina
Hartvig P, Eckernäs SA, Lindström L, Ekblom B, Bondesson U, Lundqvist H, Halldin C, Någren K, Långström B (1986) Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET). Psychopharmacology 89: 248–252
Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volavka J (1987) Multiple-dose pharmacokinetics of clozapine in patients. Pharma Res 4: 402–405
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cheng, Y.F., Lundberg, T., Bondesson, U. et al. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34, 445–449 (1988). https://doi.org/10.1007/BF01046700
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01046700